Ameliorates Renal Interstitial Fibrosis by Inhibiting Tubular Epithelial-mesenchymal Transition and
Overview
Authors
Affiliations
Epithelial-mesenchymal transition (EMT) induces the progression of renal tubulointerstitial fibrosis. Astragalus membranaceus (AM) is a traditional Chinese herbal medicine that has been demonstrated to exert anti-inflammatory and anti-cancer effects, in addition to protecting and supporting the immune system. The present study investigated the effects of AM on renal fibrosis. A mouse model of unilateral ureteral obstruction (UUO) was established and treated with various concentrations of AM (100, 200 or 400 mg/kg/day). Interstitial fibrosis markedly increased in the UUO mice. AM significantly reduced the obstruction-induced upregulation of α-smooth muscle actin (α-SMA) and downregulation of E-cadherin in the kidneys of the UUO mice (P<0.05). Furthermore, AM treatment significantly inhibited the induction of EMT and the deposition of extracellular matrix. In addition, a transforming growth factor (TGF)-β1-stimulated murine renal proximal tubule cell line (NRK-52E) was treated with various concentrations of AM (10, 20, and 40 µg/ml). E-cadherin expression levels significantly decreased and those of α-SMA significantly increased in NRK-52E cells stimulated with TGF-β1 (P<0.05). Co-treatment with AM reversed these effects (P<0.05), and AM treatment reduced TGF-β1-induced expression and Smad2/3 phosphorylation (P<0.05). These results suggested that AM antagonizes tubular EMT by inhibiting the Smad signaling pathway.
Lu K, Wu S, Lu T, Tzeng I, Kuo C, Hung Y Aging (Albany NY). 2024; 16(22):13627-13647.
PMID: 39652245 PMC: 11723655. DOI: 10.18632/aging.206170.
Research state of the herbal medicine Huangqi (Radix Astragali): A global and bibliometric study.
Chen Y, Xie M, Zhou S, Liu F Medicine (Baltimore). 2024; 103(8):e37277.
PMID: 38394541 PMC: 11309597. DOI: 10.1097/MD.0000000000037277.
Chen H, Zhou X, Yang Y, Feng Y Evid Based Complement Alternat Med. 2023; 2023:3352353.
PMID: 36793762 PMC: 9925256. DOI: 10.1155/2023/3352353.
Tiendrebeogo A, Soumagne T, Pellegrin F, Dagouassat M, Tran Van Nhieu J, Caramelle P Sci Rep. 2023; 13(1):25.
PMID: 36646720 PMC: 9842758. DOI: 10.1038/s41598-022-25993-7.
and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms.
Zhu Y, Chai Y, Xiao G, Liu Y, Xie X, Xiao W Front Pharmacol. 2022; 13:1040350.
PMID: 36408254 PMC: 9669388. DOI: 10.3389/fphar.2022.1040350.